Lilly to Launch Lantus Biosimilar in Europe in Third Quarter

Updated on

Eli Lilly & Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.